861310-73-8

Basic information

• Product Name: 3,4-dibromo-2-oxo-4-phenyl-butyric acid
• Synonyms: 3,4-dibromo-2-oxo-4-phenyl-butyric acid
• CAS NO: 861310-73-8
• Molecular Weight: 335.98
• Mol File: 861310-73-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3,4-dibromo-2-oxo-4-phenyl-butyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dibromo-2-oxo-4-phenyl-butyric acid(861310-73-8)
• EPA Substance Registry System: 3,4-dibromo-2-oxo-4-phenyl-butyric acid(861310-73-8)

Safety Data

• Hazardous Substances Data: 861310-73-8(Hazardous Substances Data)

Upstream product

• 100-52-7 benzaldehyde 
• 1914-59-6 (E)-2-oxo-4-phenyl-3-butenoic acid 

Downstream Products

• 83451-41-6 3-(α,β-dibromo-phenethyl)-1H-quinoxalin-2-one 
• 42393-28-2 4-bromo-3-hydroxy-5-phenylfuran-2(5H)-one 
• 1295568-05-6 3-benzylaminocarbonylmethyloxy-4-bromo-5-phenylfuran-2(5H)-one 
• 1295568-33-0 4-bromo-3-bromoacetyloxy-5-phenylfuran-2(5H)-one 
• 112349-14-1 1-[2-(3-oxo-3,4-dihydro-quinoxalin-2-yl)-1-phenyl-vinyl]-pyridinium; bromide 
• 63186-24-3 3-phenyl-1,2-dihydro-pyridazino[3,4-b]quinoxaline 
• 88051-11-0 3-bromo-2-phenylfuro<2,3-b>quinoxaline 
• 22298-77-7 3-phenacylidene-3,4-dihydro-1H-quinoxalin-2-one 
• 101291-14-9 3-phenylacetylquinoxaline-2(1H)-one 
• 37052-98-5 2-phenylfuro<2,3-b>quinoxaline 
• 861344-81-2 3,4-dibromo-2-oxo-4-phenyl-butyric acid methyl ester 

Relevant articles and documents

Synthesis of some substituted furan-2(5H)-ones and derived quinoxalinones as potential anti-microbial and anti-cancer agents

In search for novel anti-cancer and antimicrobial agents with promising pharmacotoxicological profile, the synthesis of some substituted 4-halofuran- 2(5H)-ones (8a-l, 9, 11) and derived halogenated quinoxalin-2(1H)-ones (12a-d) is described. Some of the halogenated furanones were readily oxidized to the corresponding 2-bromo-2-propenoic acids (13a-c) with hydrogen peroxide in alkaline medium. Twenty-two compounds were preliminary tested for their in vitro activity against three bacteria and one fungus and revealed encouraging activity. On the other hand, three compounds were screened as anti-cancer agents using cell line panel protocol and 22 compounds were subjected to cycline-dependent kinases (CDKs) inhibition screening program but were inactive. Springer Science+Business Media, LLC 2010.